Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/ Pegasys ®

Jeffrey A Gilreath, PharmD, Tsewang Tashi, MD, Soo Jin Kim, MS, Kimberly Hickman, BS, Josef T. Prchal, MD

Blood (2018) 132 (Supplement 1): 5459.

https://doi.org/10.1182/blood-2018-99-116852

Published: 2018

Journal Articles

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, MSc, Kurt Krejcy, PhD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, PhD, Maria-Theresa Krauth, MD

Blood (2018) 132 (Supplement 1): 3029.

https://doi.org/10.1182/blood-2018-99-119268

Published: 2018

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Blood (2018) 132 (Supplement 1): 459.

https://doi.org/10.1182/blood-2018-99-110569

Published: 2018

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)

Blood (2015) 126 (23): 134.

https://doi.org/10.1182/blood.V126.23.134.134

Published: 2015

Journal Articles

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Henrik Hjorth-Hansen, MD PhD, Jesper Stentoft, Johan Richter, MD PhD, Perttu Koskenvesa, MD, Arta Dreimane, MD, Kimmo Porkka, MD PhD, Tobias Gedde-Dahl, MDPhD, Bjorn Gjertsen, MD PhD, Franz X. Gruber, MDPhD, Martin Hoglund, MD PhD, Anna Lubking, MD, Kristina Myhr-Eriksson, MD, Berit Markevärn, Hanne Vestergaard, MDPhD, Ole Weis Bjerrum, MDPhD, Leif Stenke, MDPhD, Satu Mustjoki, MD PhD, Ulla Stromberg, MDPhD

Blood (2015) 126 (23): 477.

https://doi.org/10.1182/blood.V126.23.477.477

Published: 2015

Journal Articles

Rapid Clearance Of JAK2 V617F Allele Burden In Patient With Advanced Polycythemia Vera (PV) During Combination Therapy With Ruxolitinib and Peg-Interferon Alpha-2a

Mads Emil Bjørn, Karin de Stricker, Lasse Kjær, Karsten Ellemann, Hans Carl Hasselbalch, MD, DMSc

Blood (2013) 122 (21): 5241.

https://doi.org/10.1182/blood.V122.21.5241.5241

Published: 2013

Journal Articles

A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Blood (2009) 114 (22): 3280.

https://doi.org/10.1182/blood.V114.22.3280.3280

Published: 2009

Journal Articles

Randomized Phase II Study of Proteinase 3-Derived PR1 Peptide Vaccine and GM-CSF with or without PEG-Interferon ALFA-2B to Eradicate Minimal Residual Disease in Chronic Myeloid Leukemia

Alfonso QuintásCardama, Hagop M. Kantarjian, Rosa Rios, Eric D. Wieder, Ph.D., Jeffrey J. Molldrem, M.D., Jorge Cortes

Blood (2008) 112 (11): 3219.

https://doi.org/10.1182/blood.V112.11.3219.3219

Published: 2008

Journal Articles

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Diane L Nordstrom, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1590.

https://doi.org/10.1182/blood.V112.11.1590.1590

Published: 2008

Journal Articles

Maintenance Treatment after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Multiple Myeloma (MM) with a Unique Weekly Dose of Pegylated Interpheron alpha2b (Pegintron®): Preliminary Clinical Results in 30 Patients of a Phase II Multicentric Study.

Adrian Alegre, B. Aguado, J. Garcia-Laraña, J.J. Lahuerta, M.V. Mateos, R. Rodriguez-Notario, B. Navas, J.M. Fernandez-Rañada, J.F. San Miguel

Blood (2007) 110 (11): 4822.

https://doi.org/10.1182/blood.V110.11.4822.4822

Published: 2007

Journal Articles

A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.

Edmund A. Rossi, PhD, William J. McBride, Ph.D., Diane L. Nordstrom, M.S., Preeti Trisal, M.S., Thomas M. Cardillo, Ph.D., David M. Goldenberg, M.D. Sc.D., Chien-Hsing Chang, Ph.D.

Blood (2007) 110 (11): 1396.

https://doi.org/10.1182/blood.V110.11.1396.1396

Published: 2007

Journal Articles

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Elias Jabbour, MD, Hagop Kantarjian, M.D., Charles A. Koller, M.D., Stefan Faderl, M.D., Alessandra Ferrajoli, M.D., Mary Ann Richie, R.N., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Zeev Estrov, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.

Blood (2006) 108 (11): 3636.

https://doi.org/10.1182/blood.V108.11.3636.3636

Published: 2006

Journal Articles

A Weekly Dose of Pegylated Interpheron alpha-2b (Pegintron®) as Maintenance Treatment after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Multiple Myeloma (MM): Preliminary Experience.

A. Alegre, B. Aguado, J. San Miguel, J. Garcia-Laraña, F. Lara, J.J. Lahuerta, B. Navas, J. Loscertales, A. Durán, A. García, B. Iñigo, E. Moreno, J.M. Fernández-Rañada

Blood (2005) 106 (11): 5174.

https://doi.org/10.1182/blood.V106.11.5174.5174

Published: 2005

Journal Articles

Imatinib Mesylate in Polycythemia Vera. A Heterogeneous Response Pattern but a Consistent Reduction in Phlebotomy Requirements.

Hans Hasselbalch

Blood (2004) 104 (11): 4747.

https://doi.org/10.1182/blood.V104.11.4747.4747

Published: 2004

Journal Articles

PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.

Christof Scheid, MD, Andreas Draube, MD, Udo Holtick, MD, Oliver Cornely, MD, Ulrich Hacker, MD, Michael Fuchs, MD, Ute Berger, MD, Andreas Hochhaus, MD, PhD, Rüdiger Hehlmann, MD, PhD, Michael Hallek, MD, PhD

Blood (2004) 104 (11): 4662.

https://doi.org/10.1182/blood.V104.11.4662.4662

Published: 2004

Journal Articles

Treatment with Pegylated Interferon α (PegIntron) for High-Risk Essential Thrombocythemia: Results of a Phase II Study.

Christian Langer, MD, Eva Lengfelder, MD, Jurgen Thiele, MD, Hans M. Kvasnika, MD, Heike Pahl, PhD, Axel Matzdorff, MD, Barbara Stade, Stefanie Schauer, Heinz Gisslinger, MD, Hartmut Dohner, MD, Martin Griesshammer, MD

Blood (2004) 104 (11): 1522.

https://doi.org/10.1182/blood.V104.11.1522.1522

Published: 2004

Journal Articles

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

Srdan Verstovsek, M.D., Ph.D., Kristie Lawhorn, BCLS, R.N., Francis Giles, M.D., Jorge Cortes, M.D., Deborah Thomas, M.D., Guillermo Garcia-Manero, M.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Miloslav Beran, M.D., Ph.D., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1517.

https://doi.org/10.1182/blood.V104.11.1517.1517

Published: 2004

Journal Articles

A Phase II Trial of Pegylated Interferon α-2b in Polycythemia Vera and Essential Thrombocythemia. Clinical Responses, Effects on PRV-1 Expression and Impact on Quality of Life.

Jan Samuelsson, MD, PhD, Hans Hasselbalch, Oystein Bruserud, Heike Pahl, Mats Merup, Olle Linder, Yvonne Brandberg, Poul Gram-Hansen, Magnus Bjorkholm, Waleed Ghanima, Claes Malm, Berit Markevarn, Torben Mourits-Andersen, Peter Johansson, Lars Nilsson, Gunnar Birgegard

Blood (2004) 104 (11): 1518.

https://doi.org/10.1182/blood.V104.11.1518.1518

Published: 2004

NARROW

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/ Pegasys ®

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Rapid Clearance Of JAK2 V617F Allele Burden In Patient With Advanced Polycythemia Vera (PV) During Combination Therapy With Ruxolitinib and Peg-Interferon Alpha-2a

A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Randomized Phase II Study of Proteinase 3-Derived PR1 Peptide Vaccine and GM-CSF with or without PEG-Interferon ALFA-2B to Eradicate Minimal Residual Disease in Chronic Myeloid Leukemia

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Maintenance Treatment after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Multiple Myeloma (MM) with a Unique Weekly Dose of Pegylated Interpheron alpha2b (Pegintron®): Preliminary Clinical Results in 30 Patients of a Phase II Multicentric Study.

A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

A Weekly Dose of Pegylated Interpheron alpha-2b (Pegintron®) as Maintenance Treatment after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Multiple Myeloma (MM): Preliminary Experience.

Imatinib Mesylate in Polycythemia Vera. A Heterogeneous Response Pattern but a Consistent Reduction in Phlebotomy Requirements.

PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.

Treatment with Pegylated Interferon α (PegIntron) for High-Risk Essential Thrombocythemia: Results of a Phase II Study.

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

A Phase II Trial of Pegylated Interferon α-2b in Polycythemia Vera and Essential Thrombocythemia. Clinical Responses, Effects on PRV-1 Expression and Impact on Quality of Life.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only